Page results
-
Radiotherapy Department Patient Information series no. 18 - prostate brachytherapy prostate high dose rate (HDR) brachytherapy
-
This page provides information for patients visiting the Inflammatory Bowel Disease clinic.
-
This information outlines the things that you need to take home after your robotic prostatectomy.
-
This page provides an overview of the Ambulatory Care Service for adult patients.
-
Overview of the UCLH ambulatory care service for adults with cancer. This service allows people to have their cancer treatment at outpatient appointments, without needing to stay overnight in hospital.
-
Treatment and rehabilitation of adolescents and children with complex conditions service (TRACCS) at UCLH. Formerly the Children and young people's chronic fatigue syndrome service.
-
The Pathogen Genomic Unit offers access to explore the clinical applications and interpretation of pathogen genomic data for patients with a variety of infections.
-
The main theatres suite, comprising 12 operating theatres, is located on level P3 of University College Hospital.
-
Our clinical work includes thoracic surgery, obstetrics, inpatient and day-case surgery, chronic and acute pain, pre-assessment and exercise testing, imaging, endoscopy and radiotherapy.
-
Information about Cerebral AVM (Arterio Venous Malformation) Endovascular Treatment at the NHNN
File results
-
FOI/2024/0520 - Treatment of melanoma
-
FOI/2024/05523 - Dabrafenib + Trametinib cancer treatment for metastatic and adjuvant melanoma/ lung/ colorectal cancer
-
FOI/2024/0527 - Treatment for renal cell carcinoma
-
FOI/2024/0528 - Open MRIs referrals for patient size/ spend on specialist bariatric equipment 2017-2024
-
FOI/2024/0529 - Medical Associate Professionals (MAPs) at Trust
-
FOI/2024/0530 - Radiology/ imaging examinations/ patient access to radiology images
-
FOI/2024/0532 - Patient treatment/ care/ consent
-
FOI/2024/0543 - Guidelines, policies for the treatment of obesity/ pathways for Tier 3 or Tier 4 weight management services
-
FOI/2024/0356 - Treatment with Durvalumab and Nivolumab for biliary tract/ non-small cell lung cancer
-
FOI/2024/0357 - Multiple myeloma treatments